HCPCS Level II J2270: Morphine Sulfate Injection, Up to 10 mg
Commercial payers pay $3 on average nationally for this procedure.
HCPCS Level II code J2270 describes an injection of morphine sulfate, up to 10 mg, intended for analgesia; this code is used for billing a single-dose injectable opioid administered typically as an intravenous or intramuscular medication in settings such as emergency departments, hospital inpatient units, and procedural suites where parenteral pain control is provided.
For related coverage guidance, see recent payer policy updates: Epithelial Cell Cytology in Breast Cancer Risk Assessment, Antibody-Drug Conjugates, Chemotherapy Observation or Inpatient Hospitalization (for New Mexico Only).
Customize your policy alerts
Sign up for hcpcs J2270 policy alerts
Get alerted when payer policies referencing J2270 are released or updated.
Monitor payer policy activity
National Reimbursement Benchmarks
National commercial reimbursements for J2270 cluster around BUCA’s average commercial rate of $2.8, with most large payers showing medians near $2.0–$2.2. Blue Cross Blue Shield and Aetna have median rates at $2.00 and $2.00 respectively, while Cigna and UnitedHealth Group show medians of $2.20; Cigna’s mean is a notable outlier at $5.5 driven by a high $59.50 cap. This positions BUCA’s $2.8 mean modestly above several payer medians, reflecting that average commercial payment sits slightly higher than the middle of the major carriers.
Dispersion measured by the interquartile spread (P75 minus P25) is narrowest for UnitedHealth Group at $0.20 (P75 $2.40 minus P25 $2.20) and relatively tight for Aetna at $1.40 (P75 $2.30 minus P25 $0.90). Blue Cross Blue Shield and BUCA show moderate spreads of $0.80 and $1.10 respectively (BCBS P75 $2.80 minus P25 $2.00; BUCA P75 $3.00 minus P25 $1.90). Cigna exhibits the widest IQR at $2.60 (P75 $4.80 minus P25 $2.20), indicating the greatest middle-range variability among payers.